Dr. Kevin P Killeen

Dr. Kevin P Killeen Biography:

Kevin P Killeen, PhD is the Chief Scientific Officer at Matrivax Research & Development
Corp. Dr. Killeen has extensive training in the fields of molecular biology, microbiology,
protein chemistry, immunology, and vaccinology. His undergraduate BS degree is from
Stonehill College (biology and chemistry), Ph. D from University of Rhode Island
(microbiology), and post-doctoral fellowship at Harvard Medical School (molecular
genetics and protein toxin chemistry). Dr Killeen has more than 30 years of experience
in the field of biotechnology at IDEXX Corp., VRI/AVANT-Celldex Inc, and Matrivax Corp.
He has published more than 30 vaccine manuscripts, authored four chapters, written
several science reviews, is an inventor on more than ten patent/applications, and served
for 12 years as a member of the URI Dean’s Advisory Council. Dr. Killeen was the
principal investigator (PI) on vaccine related grants and contracts exceeding $11 MM
and coordinated greater than $13 MM in funding from the Bill & Melinda Gates
Foundation. Career highlights include the commercialization of two diagnostic tests,
directing nine (9) vaccine candidates (live-attenuated/oral and subunit/injectable) into
Phase 1 and 2 clinical trials, and guiding the clinical development of CholeraGarde ® , an
oral, single-dose cholera vaccine towards a Phase 3 clinical trial and out-licensing.
Moreover, while at VRI, Dr. Killeen identified and performed scientific due diligence on
rotavirus vaccine candidate 89-12, advanced through Phase 2b studies and ultimately
out-licensed to GSK and commercialized as Rotarix ® , a >$1 billion ‘blockbuster’ vaccine.
While at Matrivax, Dr. Killeen identified, in-licensed, and developed a protein fusion
based pneumococcal vaccine candidate, MVX01, that has completed non-human
primate (NHP) challenge and Phase 1a clinical studies.